News provided by Eli Lilly and Company Jul 23, 2026, 06:45 ET In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist
Initiation of glucagon-like peptide-1 receptor agonists was associated with lower emergency department use, fewer hospitalizations, and reduced escalation to additional preventive therapies compared with topiramate in adults with chronic migraine, according to a real-world cohort study to be presented at the American Academy of Neurology 78th Annual Meeting
For more details, please refer to the manual: Handling and Storage of Synthetic Peptides References: 1
MC4R is expressed in the hypothalamus, and controls feeding behavior and energy homeostasis [1, 2]
Typically occurring between ages 45 and 55, perimenopause transition is characterized by fluctuating estrogen levels and declining ovarian function that initiate a cascade of physiological and psychological changes that extend far beyond reproductive health
